1.02
price down icon6.42%   -0.07
after-market After Hours: 1.02
loading
Oncolytics Biotech Inc stock is traded at $1.02, with a volume of 2.36M. It is down -6.42% in the last 24 hours and up +35.89% over the past month. Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$1.09
Open:
$1.08
24h Volume:
2.36M
Relative Volume:
2.17
Market Cap:
$96.17M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-3.8563
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
-17.74%
1M Performance:
+35.89%
6M Performance:
+40.11%
1Y Performance:
-2.95%
1-Day Range:
Value
$1.00
$1.11
1-Week Range:
Value
$1.00
$1.2091
52-Week Range:
Value
$0.3258
$1.53

Oncolytics Biotech Inc Stock (ONCY) Company Profile

Name
Name
Oncolytics Biotech Inc
Name
Phone
-
Name
Address
-
Name
Employee
28
Name
Twitter
@oncolytics
Name
Next Earnings Date
2025-05-02
Name
Latest SEC Filings
Name
ONCY's Discussions on Twitter

Compare ONCY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ONCY
Oncolytics Biotech Inc
1.02 105.30M 0 -20.31M -21.07M -0.2645
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.41 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.14 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
330.55 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.79 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
305.74 31.87B 3.81B -644.79M -669.77M -6.24

Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-06-22 Initiated Maxim Group Buy
Feb-17-21 Initiated H.C. Wainwright Buy

Oncolytics Biotech Inc Stock (ONCY) Latest News

pulisher
Jul 29, 2025

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - PR Newswire

Jul 29, 2025
pulisher
Jul 29, 2025

What’s the recovery path for long term holders of Oncolytics Biotech Inc.High Conviction Intraday Stock Signals Detected - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Survival Data and Regulatory Greenlights Fuel Momentum in Immunotherapy Stocks - Baystreet.ca

Jul 29, 2025
pulisher
Jul 29, 2025

Oncolytics Biotech to engage FDA on potential pancreatic cancer study - Investing.com Australia

Jul 29, 2025
pulisher
Jul 29, 2025

Oncolytics Biotech sparks FDA discussions for potential pivotal pancreatic cancer trial | 2025-07-29 | Investing News - Stockhouse

Jul 29, 2025
pulisher
Jul 29, 2025

Stocks in play: Oncolytics Biotech Inc - The Globe and Mail

Jul 29, 2025
pulisher
Jul 29, 2025

Oncolytics Biotech Inc - Baystreet.ca

Jul 29, 2025
pulisher
Jul 29, 2025

Stocks In Play: Oncolytics Biotech Inc - Barchart.com

Jul 29, 2025
pulisher
Jul 29, 2025

Oncolytics Biotech Engages FDA for Pivotal Pancreatic Cancer Study - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 15:02:09 - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Oncolytics Biotech's Strategic FDA Engagement: A Catalyst for Market Redefinition in Pancreatic Cancer - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - Barchart.com

Jul 29, 2025
pulisher
Jul 28, 2025

What makes Oncolytics Biotech Inc. stock price move sharplyAI Forecast for Trending Stocks Indicates Upside - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

What are the latest earnings results for Oncolytics Biotech Inc.Maximize returns with smart investment plans - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What catalysts could drive Oncolytics Biotech Inc. stock higher in 2025Discover hidden gems in the stock market - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What institutional investors are buying Oncolytics Biotech Inc. stockInvest confidently with professional market insights - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Why is Oncolytics Biotech Inc. stock attracting strong analyst attentionReal-time trading signals for maximum returns - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How many analysts rate Oncolytics Biotech Inc. as a “Buy”Build a portfolio that outperforms consistently - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What is the dividend policy of Oncolytics Biotech Inc. stockGet real-time updates on market trends - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is it the right time to buy Oncolytics Biotech Inc. stockBuild a portfolio that outperforms consistently - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

H.C. Wainwright Analyst Reiterates Buy Rating on Oncolytics Biotech with $5 Price Target - AInvest

Jul 26, 2025
pulisher
Jul 25, 2025

Buy Rating for Oncolytics Biotech Driven by Promising Pelareorep Data in Pancreatic and Colorectal Cancers - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Oncolytics Biotech Inc. stock priceSuperior trading gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Is Oncolytics Biotech Inc. a good long term investmentRecord-breaking capital gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Oncolytics Biotech Inc. Stock Analysis and ForecastConsistently high yield - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules - Eastern Progress

Jul 23, 2025
pulisher
Jul 23, 2025

(ONC) Technical Analysis and Trading Signals (ONC:CA) - news.stocktradersdaily.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Oncolytics Biotech Inc. stockFree Stock Market Real-Time Monitoring - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Oncolytics Biotech Regains Nasdaq Compliance as of July 22, 2025 - The Globe and Mail

Jul 23, 2025
pulisher
Jul 23, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve

Jul 23, 2025
pulisher
Jul 23, 2025

Oncolytics Biotech Highlights Pelareorep’s Potential in Pancreatic Cancer at KOL Event - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential – Company AnnouncementFT.com - Financial Times

Jul 23, 2025
pulisher
Jul 23, 2025

Cancer Surge Meets Funding Crunch as Breakthrough Biotechs Line Up Milestones in 2025 - Baystreet.ca

Jul 23, 2025
pulisher
Jul 22, 2025

Pancreas Cancer Becoming Top Focus for Biotech Co.? - streetwisereports.com

Jul 22, 2025
pulisher
Jul 22, 2025

Oncolytics Biotech Regains Compliance With Nasdaq's Minimum Bid Price Rule - 富途牛牛

Jul 22, 2025
pulisher
Jul 22, 2025

Oncolytics Biotech regains compliance with Nasdaq listing requirements - Investing.com

Jul 22, 2025
pulisher
Jul 22, 2025

Oncolytics Biotech regains compliance with Nasdaq listing requirements By Investing.com - Investing.com South Africa

Jul 22, 2025
pulisher
Jul 22, 2025

Oncolytics regains Nasdaq compliance - TipRanks

Jul 22, 2025

Oncolytics Biotech Inc Stock (ONCY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.38
price up icon 10.28%
$37.27
price up icon 0.57%
$105.00
price up icon 3.19%
$26.74
price down icon 2.59%
$111.48
price down icon 1.16%
biotechnology ONC
$305.74
price up icon 3.81%
Cap:     |  Volume (24h):